Market revenue in 2024 | USD 14,644.3 million |
Market revenue in 2030 | USD 21,840.5 million |
Growth rate | 7% (CAGR from 2025 to 2030) |
Largest segment | Pharmaceuticals |
Fastest growing segment | Biologics |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics, Pharmaceuticals, Medicated Feed Additives |
Key market players worldwide | Zoetis Inc Class A, Boehringer Ingelheim, Merck & Co Inc, Elanco Animal Health Inc, Dechra Pharmaceuticals, Ceva Santé Animale, Phibro Animal Health Corp Class A, Virbac SA, Bimeda Ireland, Biogenesis Bago |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to veterinary medicine market will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 71.47% in 2024. Horizon Databook has segmented the U.S. veterinary medicine market based on biologics, pharmaceuticals, medicated feed additives covering the revenue growth of each sub-segment from 2018 to 2030.
The country’s veterinary medicine market is anticipated to grow due to the increasing number of animal healthcare centers and practitioners. For instance, according to American Veterinary Medical Association (AVMA) data, in 2022, a total of 124,069 veterinary practitioners were operating in the U.S. Of these, 78,717 veterinarians were employed in clinical practice.
These factors are anticipated to boost the U.S. veterinary medicine market. Furthermore, growing animal healthcare spending can be attributed to an increase in adoption of veterinary medicine among production animals. According to USDA National Agricultural Statistics Services, the average U.S. farm expenditure on livestock, poultry, and related expenses in 2020 was USD 19,695.
These companies are heavily investing in R&D to produce novel veterinary medicines to cater to the market demand. For instance, in October 2023, Zoetis announced the U.S. commercial launch of Librela (bedinvetmab injection), demonstrating the company’s canine innovation & dedication to providing individualized care to address the health needs of dogs.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. veterinary medicine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. veterinary medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account